Article

Molecule engineered to target neovascularization in AMD

A genetically engineered molecule designed to kill cancers by destroying their rapidly growing blood vessels offers a new line of attack against age-related macular degeneration (AMD) and other retinal conditions, said Alan Garen, PhD.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
(Image credit: Ophthalmology Times) EyeCon 2025: Oluwatosin U. Smith, MD, previews a program of collaborative care and practical learning
(mage credit: Ophthalmology Times) S. Robert Levine, MD, on the DRD Cure Accelerator: A global moonshot for retinal disease
(Image credit: Ophthalmology Times) CCOI sets the stage for global ophthalmic innovation at Stanford Summit on July 23
Related Content
(Image credit: SeeWhatMatters)
August 22nd 2025

Q&A: AEVR's executive director on #SeeWhatMatters and safeguarding the National Eye Institute

3 Things You Should Know About the GA Pipeline
August 22nd 2025

3 Things You Should Know About Interventional Glaucoma Comanagement

(Image credit: AdobeStock/InkInvent) FDA clears path for US IDE study of Myra Vision’s titratable glaucoma therapy
August 22nd 2025

FDA clears path for US IDE study of Myra Vision’s titratable glaucoma therapy

Patient-Centered Treatment Strategies in the Management of nAMD and DME
August 22nd 2025

Patient-Centered Treatment Strategies in the Management of nAMD and DME

(Image credit: AdobeStock/ipopba) Robotic precision: Elevating the state of laser cataract surgery
August 22nd 2025

Robotic precision: Elevating the state of laser cataract surgery

(Image credit: AdobeStock/zabhie) AI applications in cataract surgery: A surgeon’s perspective
August 22nd 2025

AI applications in cataract surgery: A surgeon’s perspective

© 2025 MJH Life Sciences

All rights reserved.